2008-12-02 19:13:03 -
Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) has posted an Update on the company website that discusses the company?s development plans for OxycyteŽ. Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier.
In the Update, Chris J. Stern, DBA, company chairman and CEO, discusses plans for new clinical trials for Oxycyte in Traumatic Brain Injury as well as additional business and
development plans for Oxycyte in other indications. That Update, dated December 2, 2008, can be found on the investor relations page of the company website at www.oxybiomed.com.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes. For further information, visit www.oxybiomed.com.
Abe Wischnia & Associates
Abe Wischnia
619-795-2345
